BACKGROUND AND OBJECTIVES: The multi-modal treatment of retroperitoneal sarcoma has seen increased use of neoadjuvant radiation. However, its effect on local recurrence and survival remain controversial. We aimed to synthesize and evaluate the literature. METHODS: The review was conducted according the recommendation of the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group with pre-specified inclusion and exclusion criteria. RESULTS: Of 8,701 citations collected, 15 articles reported on 464 patients. The median age was 56 years (45-64). The predominant histological subtypes were liposarcoma (51.54%) and leiomyosarcoma (23.26%). Tumor differentiation composed of 37.1% well-, 12.8% moderate-, 46.0% poorly-, and 4.1% undifferentiated. Most studies featured external beam radiation therapy (EBRT) treatment regimen with some who included patients treated with IMRT instead. Median follow-up averaged 41.4 months (19-106 months). Median 5-year OS, PFS, and LRR rates were 58%, 71.5%, and 25%. Using the NCI CTCAE, toxicities from Grade 1 (Mild) through Grade 5 (death) were experienced by 18.8%, 10.2%, 16.3%, 0.7%, and 1.6% of patients. CONCLUSIONS: NART is a safe to use for RPS, but its effect toward survival and local control remains unclear. Without randomized control trials, common reporting criteria for pro- and retrospective studies are needed to allow comparison between studies. J. Surg. Oncol. 2016;113:628-634.
BACKGROUND AND OBJECTIVES: The multi-modal treatment of retroperitoneal sarcoma has seen increased use of neoadjuvant radiation. However, its effect on local recurrence and survival remain controversial. We aimed to synthesize and evaluate the literature. METHODS: The review was conducted according the recommendation of the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group with pre-specified inclusion and exclusion criteria. RESULTS: Of 8,701 citations collected, 15 articles reported on 464 patients. The median age was 56 years (45-64). The predominant histological subtypes were liposarcoma (51.54%) and leiomyosarcoma (23.26%). Tumor differentiation composed of 37.1% well-, 12.8% moderate-, 46.0% poorly-, and 4.1% undifferentiated. Most studies featured external beam radiation therapy (EBRT) treatment regimen with some who included patients treated with IMRT instead. Median follow-up averaged 41.4 months (19-106 months). Median 5-year OS, PFS, and LRR rates were 58%, 71.5%, and 25%. Using the NCI CTCAE, toxicities from Grade 1 (Mild) through Grade 5 (death) were experienced by 18.8%, 10.2%, 16.3%, 0.7%, and 1.6% of patients. CONCLUSIONS: NART is a safe to use for RPS, but its effect toward survival and local control remains unclear. Without randomized control trials, common reporting criteria for pro- and retrospective studies are needed to allow comparison between studies. J. Surg. Oncol. 2016;113:628-634.
Authors: M Ballesteros; N Montero; A López-Pousa; G Urrútia; I Solà; G Rada; H Pardo-Hernandez; X Bonfill Journal: Clin Transl Oncol Date: 2019-03-14 Impact factor: 3.405
Authors: Antonio Chiappa; Emilio Bertani; Gabriella Pravettoni; Andrew Paul Zbar; Diego Foschi; Giuseppe Spinoglio; Bernardo Bonanni; Gianluca Polvani; Federico Ambrogi; Maria Laura Cossu; Carlo Ferrari; Marco Venturino; Cristiano Crosta; Luca Bocciolone; Roberto Biffi Journal: Indian J Surg Date: 2018-01-31 Impact factor: 0.656
Authors: B T Turner; L Hampton; D Schiller; L A Mack; C Robertson-More; H Li; M L Quan; A Bouchard-Fortier Journal: Curr Oncol Date: 2019-12-01 Impact factor: 3.677
Authors: Patrick B Schwartz; Kara Vande Walle; Emily R Winslow; Cecilia G Ethun; Thuy B Tran; George Poultsides; Jennifer Tseng; Kevin Roggin; Valerie Grignol; John Harrison Howard; Bradley A Krasnick; Ryan C Fields; Harveshp Mogal; Callisia N Clarke; Rebecca Senehi; Konstantinos Votanopoulos; Kenneth Cardona; Daniel E Abbott Journal: Sarcoma Date: 2019-06-02